Home Investing Eli Lilly sales soar 45% on weight loss drug demand, but drugmaker cuts profit outlook after cancer treatment deal
Investing

Eli Lilly sales soar 45% on weight loss drug demand, but drugmaker cuts profit outlook after cancer treatment deal

by admin
written by admin

Eli Lilly said sales of weight loss drug Zepbound and diabetes treatment Mounjaro surged in the first quarter.

You may also like

Netflix’s advertising strategy shift is starting to pay...

Procter & Gamble earnings top estimates, but shrinking...

P&G’s weak quarter is a clearing event that...

Procter & Gamble is selling diapers made with...

United Airlines could hit record earnings after strong...

Johnson & Johnson forecasts 2026 profit above Wall...

Netflix posts narrow earnings beat, reports 325 million...

3M forecasts annual profit below estimates amid sluggish...

Earnings playbook: Netflix and this chipmaker are among...

BlackRock’s earnings pass our test with flying colors....

Leave a Comment

Save my name, email, and website in this browser for the next time I comment.

ten + two =

Privacy Policy - Terms and Conditions